非小细胞肺癌术后放疗相关肺毒性风险因素分析

doi:10.3760/cma.j.issn.1004-4221.2019.10.004

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的评估手术后接受现代放疗技术的非小细胞肺癌(NSCLC)患者术后有症状的放射性肺毒性(SRILT)发生率及风险因素。方法回顾性分析2002-2011年于中国医学科学院肿瘤医院行手术治疗且接受术后三维适形或调强放疗的NSCLC患者。采用不良反应评价标准3.0版进行放疗相关肺毒性分级,≥2级定义为SRILT。Logistic回归模型评估潜在的临床因素和剂量学因素。结果 227例患者入组,包括190例肺叶切除术和37例全肺切除术者。23例(10.1%)患者发生了SRILT,均为肺叶切除术后放疗者。放射性肺炎2级17例、3级5例、4级1例。单因素分析结果显示术后同步放化疗、较大的PTV、平均肺剂量、V20-V40与SRILT发生率相关(P=0.015、0.048、<0.001),多因素分析结果显示术后同步放化疗、V20与SRILT发生相关(P=0.017、0.009)。结论 NSCLC术后放疗后SRILT发生率较低,同步放化疗及V20为SRILT发生的影响因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	范诚诚
	赵路军
	毕楠
	惠周光
	梁军
	吕纪马
	王小震
	葛红
	王绿化

关键词 ：肺肿瘤/外科学, 肺肿瘤/放射疗法, 放射性肺损伤

Abstract：Objective To evaluate the incidence and risk factors of symptomatic radiation-induced lung toxicity (SRILT) in non-small cell lung cancer (NSCLC) patients treated with modern radiotherapy after surgery. Methods Clinical data of consecutive NSCLC patients treated with postoperative three-dimensional conformal or intensity-modulated radiotherapy in Cancer Hospital of Chinese Academy of Medical Sciences between November 2002 and December 2011 were retrospectively analyzed. According to the Common Terminology Criteria for Adverse Events (CTCAE, version 3.0), SRILT was defined as ≥grade 2 radiation-induced lung toxicity. Potential clinical risk factors and dosimetric parameters for SRILT were evaluated using logistic regression model. Results Among 227 enrolled patients, 190 cases underwent lobectomy and 37 patients received pneumonectomy. Twenty-three patients (10.1%) developed SRILT after lobectomy. Seventeen patients experienced grade 2 SRILT, 5 cases of grade 3 SRILT and 1 case of grade 4 SRILT. Univariate analysis showed that postoperative concurrent chemoradiotherapy, relatively large PTV, mean lung dose and V20- V40 were significantly correlated with the incidence of SRILT (P=0.015, 0.048 and<0.001). Multivariate analysis demonstrated that postoperative concurrent chemoradiotherapy and V20 were significantly associated with the incidence of SRILT (P=0.017 and P=0.009). Conclusions The incidence of SRILT is relatively low in NSCLC patients after postoperative radiotherapy. Concurrent chemoradiotherapy and V20 are risk factors of SRILT.

Key words： Lung neoplasm/surgery Lung neoplasm/radiotherapy Radiation-induced lung injury

收稿日期: 2018-12-19

基金资助:国家自然科学基金(81773230)

通讯作者: 王绿化,Email:wlhwq@yahoo.com;葛红,Email:gehong666@126.com

引用本文:

范诚诚,赵路军,毕楠等. 非小细胞肺癌术后放疗相关肺毒性风险因素分析[J]. 中华放射肿瘤学杂志, 2019, 28(10): 735-740.

Fan Chengcheng,Zhao Lujun,Bi Nan et al. Analysis of risk factors of radiation-induced lung toxicity in non-small cell lung cancer patients treated with postoperative radiotherapy[J]. Chinese Journal of Radiation Oncology, 2019, 28(10): 735-740.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2019.10.004 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2019/V28/I10/735

[1] PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer:systematic review and meta-analysis of individual patient data from nine randomised controlled trials[J]. Lancet,1998,352(9124):257-263.
[2] Okawara G,Ung YC,Markman BR,et al. Postoperative radiotherapy in stage Ⅱ or ⅢA completely resected non-small cell lung cancer:a systematic review and practice guideline[J]. Lung Cancer,2004,44(1):1-11. DOI:10.1016/j.lungcan.2003.09.020.
[3] Lally BE,Zelterman D,Colasanto JM,et al. Postoperative radiotherapy for stage Ⅱ or Ⅲ non-small-cell lung cancer using the surveillance,epidemiology,and end results database[J]. J Clin Oncol,2006,24(19):2998-3006. DOI:10.1200/JCO.2005.04.6110.
[4] Lally BE,Detterbeck FC,Geiger AM,et al. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy:analysis of the surveillance,epidemiology,and end results database[J]. Cancer,2007,110(4):911-917. DOI:10.1002/cncr.22845.
[5] Hope AJ,Lindsay PE,El Naqa I,et al. Modeling radiation pneumonitis risk with clinical,dosimetric,and spatial parameters[J]. Int J Radiat Oncol Biol Phys,2006,65(1):112-124. DOI:10.1016/j.ijrobp,2005.11.046:
[6] Inoue A,Kunitoh H,Sekine I,et al. Radiation pneumonitis in lung cancer patients:a retrospective study of risk factors and the long-term prognosis[J]. Int J Radiat Oncol Biol Phys,2001,49(3):649-655.
[7] Rancati T,Ceresoli GL,Gagliardi G,et al. Factors predicting radiation pneumonitis in lung cancer patients:a retrospective study[J]. Radiother Oncol,2003,67(3):275-283.
[8] Claude L,Perol D,Ginestet C,et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer:clinical and dosimetric factors analysis[J]. Radiother Oncol,2004,71(2):175-181. DOI:10.1016/j.radonc.2004.02.005.
[9] Graham MV,Purdy JA,Emami B,et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)[J]. Int J Radiat Oncol Biol Phys,1999,45(2):323-329.
[10] Hernando ML,Marks LB,Bentel GC,et al. Radiation-induced pulmonary toxicity:a dose-volume histogram analysis in 201 patients with lung cancer[J]. Int J Radiat Oncol Biol Phys,2001,51(3):650-659.
[11] Palma DA,Senan S,Tsujino K,et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer:an international individual patient data meta-analysis[J]. Int J Radiat Oncol Biol Phys,2013,85(2):444-450. DOI:10.1016/j.ijrobp.2012.04.043.
[12] Wang L,Wu S,Ou G,et al. Randomized phase Ⅱ study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage Ⅲ non-small cell lung cancer[J]. Lung Cancer,2012,77(1):89-96. DOI:10.1016/j.lungcan.2012.02.011.
[13] Zhao L,Ji W,Ou G,et al. Risk factors for radiation-induced lung toxicity in patients with non-small cell lung cancer who received postoperative radiation therapy[J]. Lung Cancer,2012,77(2):326-330. DOI:10.1016/j.lungcan.2012.03.017.
[14] Parashar B,Edwards A,Mehta R,et al. Chemotherapy significantly increases the risk of radiation pneumonitis in radiation therapy of advanced lung cancer[J]. Am J Clin Oncol,2011,34(2):160-164. DOI:10.1097/COC.0b013e3181d6b40f.
[15] Matsuo Y,Shibuya K,Nakamura M,et al. Dose—volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer[J]. Int J Radiat Oncol Biol Phys,2012,83(4):e545-549. DOI:10.1016/j.ijrobp.2012.01.018.
[16] Barriger RB,Forquer JA,Brabham JG,et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys,2012,82(1):457-462. DOI:10.1016/j.ijrobp.2010.08.056.
[17] Miles EF,Kelsey CR,Kirkpatrick JP,et al. Estimating the magnitude and field-size dependence of radiotherapy-induced mortality and tumor control after postoperative radiotherapy for non-small-cell lung cancer:calculations from clinical trials[J]. Int J Radiat Oncol Biol Phys,2007,68(4):1047-1052. DOI:10.1016/j.ijrobp.2007.02.028.
[18] Boonyawan K,Gomez DR,Komaki R,et al. Clinical and dosimetric factors predicting grade>/=2 radiation pneumonitis after postoperative radiotherapy for patients with non-small cell lung carcinoma[J]. Int J Radiat Oncol Biol Phys,2018,101(4):919-926. DOI:10.1016/j.ijrobp.2018.04.012.
[19] Saynak M,Higginson DS,Morris DE,et al. Current status of postoperative radiation for non-small-cell lung cancer[J]. Semin Radiat Oncol,2010,20(3):192-200. DOI:10.1016/j.semradonc.2010.01.008.
[20] Dai H,Hui Z,Ji W,et al. Postoperative radiotherapy for resected pathological stage ⅢA-N2 non-small cell lung cancer:a retrospective study of 221 cases from a single institution[J]. Oncologist,2011,16(5):641-650. DOI:10.1634/theoncologist.2010-0343.
[21] Dehing-Oberije C,De Ruysscher D,van Baardwijk A,et al. The importance of patient characteristics for the prediction of radiation-induced lung toxicity[J]. Radiother Oncol,2009,91(3):421-426. DOI:10.1016/j.radonc.2008.12.002.
[22] Kong FM,Ten Haken R,Eisbruch A,et al. Non-small cell lung cancer therapy-related pulmonary toxicity:an update on radiation pneumonitis and fibrosis[J]. Semin Oncol,2005,32(2 Suppl 3):S42-54.
[23] Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer:pulmonary function,prediction,and prevention[J]. Int J Radiat Oncol Biol Phys,2005,63(1):5-24. DOI:10.1016/j.ijrobp.2005.03.047.
[24] Vogelius IR,Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis[J]. Acta Oncol,2012,51(8):975-983. DOI:10.3109/0284186X.2012.718093.
[25] Tucker SL,Liu HH,Liao Z,et al. Analysis of radiation pneumonitis risk using a generalized Lyman model[J]. Int J Radiat Oncol Biol Phys,2008,72(2):568-574. DOI:10.1016/j.ijrobp.2008.04.053.
[26] Wang J,Cao J,Yuan S,et al. Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity[J]. Int J Radiat Oncol Biol Phys,2013,85(3):798-804. DOI:10.1016/j.ijrobp.2012.06.040.
[27] Zhao L,Wang L,Ji W,et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer:a combined analysis from Beijing and Michigan[J]. Int J Radiat Oncol Biol Phys,2009,74(5):1385-1390. DOI:10.1016/j.ijrobp.2008.10.065.
[28] Yang M,Zhang L,Bi N,et al. Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy[J]. Int J Radiat Oncol Biol Phys,2011,79(5):1402-1407. DOI:10.1016/j.ijrobp.2009.12.042.
[29] Zhao L,Wang L,Ji W,et al. Association between plasma angiotensin-converting enzyme level and radiation pneumonitis[J]. Cytokine,2007,37(1):71-75. DOI:10.1016/j.cyto.2007.02.019.
[30] 王绿化,傅小龙,陈明,等. 放射性肺损伤的诊断与治疗[J]. 中华放射肿瘤学杂志,2015,24(1):4-9. DOI:10.3760/cma.j.issn.1004-4221.2015.01.003.
Wang LH,Fu XL,Chen M,et al. Diagnosis and treatment of radiation-induced lung injury[J]. Chin J Radiat Oncol,2015,24(1):4-9. DOI:10.3760/cma.j.issn.1004-4221.2015.01.003.